5 Worst Performing Healthcare Stocks in 2023

3. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

YTD Share Price Decline as of August 13: 35.58%

Number of Hedge Fund Holders: 42

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biotechnology company that focuses on the research and treatment for autoimmune and inflammatory diseases. On July 31, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced a Q2 GAAP loss per share of $1.02, which was an improvement over market estimates by $0.30. In line with this, the revenue was reported at $94.9 million, exceeding analysts’ expectations by $23.78 million. 

According to Insider Monkey’s first quarter database, 42 hedge funds were bullish on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), compared to 38 hedge funds in the last quarter. Kurt Von Emster’s VenBio Select Advisor held the largest position in the company, with 1.1 million shares worth $733 million. 

Follow Apellis Pharmaceuticals Inc. (NASDAQ:APLS)